An interventional study of 200 ml dairy and 100 ml milk in Osteopenia, sponsored by University of Aarhus. Active, not recruiting at 1 site in Denmark. Open to female participants aged Up to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by University of Aarhus · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Bone Diseases, Metabolic with a site in Denmark — 2 open to participants now, 5 under way, none of them phase 3. Bone Diseases, Metabolic · Denmark.
Among the 26 studies in Bone Diseases, Metabolic with a site in Denmark, this one is the 22nd largest by planned enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2025, is one of 9 with no phase, and was the 25th registered.
663 studies on the registry are indexed under Bone Diseases, Metabolic; 95 are open to participants now.
Browse Bone Diseases, Metabolic studies →2 of the 26 studies in Bone Diseases, Metabolic with a site in Denmark are open now. Recruiting first, the newest first:
Odense University Hospital · Sites in Denmark
Ages 60–75 · Women only · Healthy volunteers
Filip Krag Knop · Sites in Denmark
Ages 18–60 · Healthy volunteers
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 64 Bone Diseases, Metabolic studies recruiting now, 28 (44%) set no upper age limit and 28 (44%) stop at 75 or younger; 12 take children under 18; 22 take healthy volunteers.
This study: Up to 80 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 5 · Phase 4 1
First in 2011; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 13 is below the median of 60 across 510 interventional studies indexed under Bone Diseases, Metabolic.
Median enrollment 85 across the 23 interventional studies, 20 across the 3 observational. Of the 18 that completed or were terminated, 6 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 26 have an industry lead sponsor. The 10 most frequent:
University of Aarhus is the lead sponsor of 1,303 studies on the registry; 190 are open to participants now.
University of Aarhus has 5 studies filed under Bone Diseases, Metabolic — fewer than ten, so there is no comparison to draw.
3 of the studies in Bone Diseases, Metabolic with a site in Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06050577Odense University HospitalThe Effect of Oral Semaglutide on Bone Turnover in Patients With T2D: a Randomized Placebo-controlled Clinical Trial | 2027-01-15 |
| NCT07191353Odense University HospitalResistance Training and Rapamycin to Enhance Bone Formation in Postmenopausal Women | 2027-03-01 |
| NCT07056322University of AarhusOptimal Meals to Reduce Bone Resorption in Women With Osteopenia | 2027-04 |
Add all 3 to your calendar (.ics) → With an account.
Among the 26 studies in Bone Diseases, Metabolic with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to investigate whether different types of small meals can help reduce bone loss in postmenopausal women with osteopenia, a condition where bone density is lower than normal and may lead to osteoporosis.
The main hypothesis is:
- A small amount of dairy (100 ml) is just as effective as a larger meal containing dairy and banana in reducing bone resorption.
Based on this, the study aims to answer the following questions:
- Which type and size of meal is most effective in reducing bone resorption?
Researchers will compare five different types of meals to a fasting control day to determine which meals best reduce markers of bone loss in the blood.
Participants will attend six clinical visits: five involving the intake of different test meals, and one control visit involving fasting. The participants will have blood samples taken over a period of 6 hours after each meal or fasting period to measure markers of bone metabolism.
This study aims to identify a simple, non-drug-based strategy to support bone health and help prevent progression to osteoporosis.
This project investigates whether administration of a meal can reduce bone resorption and thereby, if used strategic, prevent the development of osteoporosis in postmenopausal women with osteopenia, as measured by bone turnover markers and bone density. Furthermore, it is investigated which type and size of meal is optimal for bone health in osteopenia.
The project comprises of one hypotheses:
- 100 ml dairy is as effective as larger amounts of dairy and banana in decreasing bone resorption.
Osteopenia is a prevalent condition and is a precursor to osteoporosis and fractures. In 2011 it is estimated that osteoporotic fractures resulted a total cost of 1.6 billion EUR in Denmark. Osteopenia is diagnosed by a low bone mineral density (BMD), with a T-score between -1.1 and - 2.4, whereas osteoporosis is diagnosed by a T-score of ≤2.5. In postmenopausal women, it is estimated that 43 % have osteopenia. The current recommendation to prevent fractures in osteopenia is sufficient intake of vitamin D and calcium, besides smoking cessation, physical activity, and moderate alcohol intake. In case of osteoporosis, additional anti-osteoporotic medications are recommended, which have been shown to reduce fracture rates. However, effective non-pharmacologic remedies to prevent progression from osteopenia to osteoporosis are urgently needed and the potential of timing of meals in this context should therefore be explored. Osteopenia and osteoporosis are caused by an increased bone resorption to bone formation ratio which decreases BMD and increases fractures. During the bone resorption and bone formation phases; products are released to the bloodstream and can be measured as bone turnover markers. Carboxy-terminal collagen crosslinks (CTX) is a bone resorption marker and procollagen type I Npropeptide (P1NP) is a bone formation marker and they are internationally recommended as the standard bone turnover markers. Following a meal, bone resorption decreases. The gut hormone; glucagon-like peptide 2 (GLP-2) is released to the circulation following a meal and reduces bone resorption, as measured by CTX, by 50 %. In humans bone resorption is highly increased during the night time (fasting state) and gut hormones have therefore been suggested as treatments for osteoporosis. In a previous study, GLP-2 was administered subcutaneously before bedtime for 120 days and showed a decrease in nightly CTX levels and an increase in bone mineral density at the hip and no signs of tachyphylaxis during the treatment. The investigators have shown that a meal suppresses CTX levels for as long as six hours with a simultaneous increase in GLP-2 and that the oral administration of nutrients is essential for a reduction in CTX. The investigators have great experience in conducting clinical trials assessing bone health. In this project it is investigated which type and size of meals reduce CTX most profoundly.
The meals in this study are selected as 3.5 % fatty dairy or banana as these are commonly used smaller meals. Furthermore, the gastric emptying of a dairy depends on the meal size, and fat reduces the gastric emptying, whereas banana contains fibers and may thus have a shorter gastric emptying. Yoghurt is expected to have slower gastric emptying than milk primarily due to its higher viscosity. Additionally yoghurt is a more fermented product compared to milk, potentially affecting the postprandial gut hormone response differently. Psyllium and banana (pectin fibers) are both dietary fiber sources but differ in fiber composition and solubility, which may lead to different effects on gastric emptying and gut hormone responses. The fiber content differs between banana and psyllium, with psyllium being more concentrated. We aim to adjust the fiber content to be approximately equivalent, so participants will receive 4-5 g of psyllium (1 teaspoon), providing about the same amount of fiber as 100 g of banana.
The results from this study will be used for a follow up study in which the effects on bone health of meal administration over a longer period will be assessed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants will receive each of the six interventions (five different meals and one fasting control) in randomized order, with a minimum 1 week washout between test days. The order of the interventions is individually randomized. Blood samples will be collected at arrival and hourly during each visit to assess bone turnover markers.
Dietary Supplement: 200 ml dairy · Dietary Supplement: 100 ml milk · Dietary Supplement: 100 g banana · Dietary Supplement: 100 ml dairy and fibers · Other: Fasting (control) · Dietary Supplement: 100 ml dairy
Participants consume the meal after a fasting baseline bloodsample. Bloodsamples are collected over a six-hour period to evaluate postpandrial changes in bone turnover markers.
Participants consume the meal after a fasting baseline bloodsample. Bloodsamples are collected over a six-hour period to evaluate postpandrial changes in bone turnover markers.
Participants consume the meal after a fasting baseline bloodsample. Bloodsamples are collected over a six-hour period to evaluate postpandrial changes in bone turnover markers.
Participants consume the meal after a fasting baseline bloodsample. Bloodsamples are collected over a six-hour period to evaluate postpandrial changes in bone turnover markers.
Participants consume the meal after a fasting baseline bloodsample. Bloodsamples are collected over a six-hour period to evaluate postpandrial changes in bone turnover markers.
Participants consume the meal after a fasting baseline bloodsample. Bloodsamples are collected over a six-hour period to evaluate postpandrial changes in bone turnover markers.
Bone resoroption
The primary endpoint of the study is difference in the area under curve of the bone resorption marker CTX during the different study days
Time frame: From enrollment through six study visits over a period of approximately 12 weeks
Change in bone formation marker P1NP
Secondary outcome assesing changes in the bone formation marker P1NP
Time frame: From enrollment through six study visits over a period of approximately 12 weeks
Changes in osteocalcin levels
Secondary outcome assesing changes in the bone turnover marker osteocalcin
Time frame: From enrollment through six study visits over a period of approximately 12 weeks
Changes in immune respons (Treg/Th17 cell ratio)
Secondary outcome assesing changes in the immune cell composition (Treg/Th17 cell ratio)
Time frame: From enrollment through six study visits over a period of approximately 12 weeks
Changes in the incretin hormone GLP-2
Secondary outcome assesing changes in levels of GLP-2
Time frame: From enrollment through six study visits over a period of approximately 12 weeks
Plan to share: Undecided
Started Dec 2025 (actual). Primary completion is estimated for Apr 2027, 16 months after the start.
Of 161 non-industry interventional studies with no phase under Bone Diseases, Metabolic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 38. This study's planned 16 months is below that.
Counting every sponsor, half of 177 studies reached it within 22 months; a quarter within 10 and three quarters within 38.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Oct 2026 → Apr 2027 and completion Oct 2026 → May 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: cow's milk · Banana